drugset / Trial / NCT05334277
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2
Recruiting
280 enrolled
Sun Yat-sen University
Allist Pharmaceuticals, Inc. · collabGeneCast Biotechnology Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported. This study aims to investigate the efficacy and safety of combination therapy compared with furmonertinib monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.
Timeline
- Start
- 2022-05-06
- Primary completion
- 2025-02-28
- Completion
- 2028-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Firmonertinib | Small molecule | 80 mg | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |